Journal
ARCHIVES OF DERMATOLOGICAL RESEARCH
Volume 313, Issue 5, Pages 319-325Publisher
SPRINGER
DOI: 10.1007/s00403-020-02151-5
Keywords
Basal cell carcinoma; Squamous cell carcinoma; Upstaging; Mohs surgery; Nonmelanoma skin cancer
Categories
Ask authors/readers for more resources
The incidence of NMSC is increasing in the US, with a significant proportion being upstaged during surgery. Biopsy sampling error and variability in reporting contribute to discrepancies. More comprehensive treatment modalities may be necessary for high-risk tumors.
The incidence of nonmelanoma skin cancer (NMSC) in the United States is increasing with approximately 3.6 million cases diagnosed per year. The staging and treatment of NMSC is guided by histologic subtype based on skin biopsy, along with other tumor-specific factors. However, a biopsy only represents a portion of the tumor, so there is a risk of upstaging at the time of definitive surgery. We conducted a review of the literature and found that a significant proportion of NMSC were upstaged during surgery. The rate of upstaging of basal cell carcinoma (BCC) was 7-31% and that of squamous cell carcinoma in situ (SCCIS) to squamous cell carcinoma (SCC) was 3-39%. Biopsy sampling error and variability in interpreting and reporting by dermatopathologists contribute to these discrepancies. It is pertinent to consider more comprehensive treatment modalities for tumors at high risk for upstaging. Diligence to identify tumors at higher risk for upstaging will allow clinicians to optimize management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available